Browse News
Filter News
Found 503,796 articles
-
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
-
For some time, the difference between a biotechnology company and a pharmaceutical company was straightforward. A biotechnology focused on developing drugs with a biological basis. Pharmaceutical companies focused on drugs with a chemical basis. But what about nanotechnology? Is that biotechnology?
-
The Fourth Industrial Revolution, according to Klaus Schwab, founder and executive chairman of the World Economic Forum Geneva, “is building on the Third, the digital revolution that has been occurring since the middle of the last century. It is characterized by a fusion of technologies that is b...
-
AstraZeneca and its research-and-development unit MedImmune, announced positive overall survival (OS) data for its Phase III PACIFIC trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
-
The U.S. Food and Drug Administration (FDA) gave BioMarin Pharmaceutical a thumbs-up for its Palynziq (pegvaliase-pqpz) to treat phenylketonuria (PKU).
-
Magenta Therapeutics Sets Sights on $100 Million IPO To Advance Bone Marrow Transplant Programs
5/25/2018
Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing. -
One month after Prothena Corporation shuttered its NEOD001 program for AL amyloidosis following a Phase IIb failure, the company initiated a reorganization that includes a workforce reduction of 57 percent.
-
A tangled web has been woven at Michigan-based Rockwell Medical. The board of directors has fired the chief executive officer and chief financial officer.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
Credibility is an attribute that is part of your being, which is why you can’t fake it or establish it very quickly.
-
Alexion Offer for Wilson Therapeutics Accepted
5/25/2018
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7 percent of the total number of shares and votes in Wilson Therapeutics.
-
Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada
5/25/2018
Acquisition represents our first entry into the Canadian market and further expands our sterile processing capability, which is in very high demand
-
IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer
5/25/2018
IMFINZI met the second primary endpoint of overall survival which was both statistically significant and clinically meaningful at a planned interim analysis
-
Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer
5/25/2018
The "Reducer" is a product for patients suffering from refractory angina
-
LabCorp to Become a Preferred National Laboratory for Aetna
5/25/2018
Agreement Expands Access to High-Quality, High-Value Laboratory Services for All Aetna Members
-
Itch, Scratch, Rash: Allergic Contact Dermatitis, The Lesser Known Allergy
5/25/2018
Spring has sprung and it's no wonder May is National Allergy Month.
-
MedAmerica Properties Inc. Appoints Real Estate Veteran Vineet Bedi, CFA to the Board of Directors
5/25/2018
MedAmerica Properties Inc. (OTC: MAMP) ("MedAmerica" or the "Company") today announced that Vineet Bedi, CFA has been appointed to the Board of Directors, effective May 23, 2018.
-
BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation
5/25/2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the Federal "Right-to-Try" bill.
-
Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with ThromboGenics
5/25/2018
Phase 1 clinical study initiated evaluating THR-149 in diabetic macular edema (DME) Alliance extended to develop additional Bicycles for ophthalmology
-
Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence
5/25/2018
Indivior PLC (LON: INDV) today announced that it has filed a regulatory submission with Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous use, for the treatment of opioid dependence within a framework of medical, social and psychological treatment. If approved, SUBLOCADE will be marketed by Indivior Pty Ltd in Australia.